Open AccessThis article is
- freely available
Targeted Therapy in Nonmelanoma Skin Cancers
Department of Dermatology, University of Rome “Tor Vergata”, Via Montpellier 1, 00199, Rome, Italy
* Author to whom correspondence should be addressed.
Received: 11 March 2011; in revised form: 11 April 2011 / Accepted: 26 April 2011 / Published: 3 May 2011
Abstract: Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in light-skinned populations, and includes mainly Basal Cell Carcinomas (BCC), representing around 75% of NMSC and Squamous Cell Carcinomas (SCC). The incidence of these tumors is continuously growing. It was found that the overall number of procedures for NMSC in US rose by 76%, from 1,158,298 in 1992 to 2,048,517 in 2006. Although mortality from NMSC tends to be very low, clearly the morbidity related to these skin cancers is very high. Treatment options for NMSC include both surgical and nonsurgical interventions. Surgery was considered the gold standard therapy, however, advancements in the knowledge of pathogenic mechanisms of NMSCs led to the identification of key targets for drug intervention and to the consequent development of several targeted therapies. These represent the future in treatment of these common forms of cancer ensuring a high cure rate, preservation of the maximal amount of normal surrounding tissue and optimal cosmetic outcome. Here, we will review recent advancements in NMSC targeted therapies focusing on BCC and SCC.
Keywords: basal cell carcinoma (BCC); squamous cell carcinoma (SCC); EGFR; SMO inhibitor; COX2
Citations to this Article
Cite This Article
MDPI and ACS Style
Spallone, G.; Botti, E.; Costanzo, A. Targeted Therapy in Nonmelanoma Skin Cancers. Cancers 2011, 3, 2255-2273.
Spallone G, Botti E, Costanzo A. Targeted Therapy in Nonmelanoma Skin Cancers. Cancers. 2011; 3(2):2255-2273.
Spallone, Giulia; Botti, Elisabetta; Costanzo, Antonio. 2011. "Targeted Therapy in Nonmelanoma Skin Cancers." Cancers 3, no. 2: 2255-2273.